The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease

Project Information

DAVIAD

Grant agreement ID: 602779

Project closed

Start date 1 December 2013

End date 30 June 2018

Funded under

• Specific Programme "Cooperation": Health

Total cost

€ 8 362 660,60

EU contribution

€ 5 924 893,00

Coordinated by

APITOPE INTERNATIONAL NV
Belgium

• New treatment on the horizon for Graves' disease
  EN